HDAC inhibitors: Promising agents for leukemia treatment

Area of Science:

• Epigenetics
• Molecular Biology
• Oncology

Background:

• Epigenetic modifications, including histone deacetylase (HDAC) activity, are crucial in cancer development.
• Aberrant HDAC expression is common across various cancer types, making HDACs therapeutic targets.
• HDAC inhibitors (HDACi) offer a promising therapeutic strategy, with vorinostat being the first FDA-approved HDACi for cutaneous T-cell lymphoma.

Purpose of the Study:

• To review the mechanisms by which HDAC inhibitors exert therapeutic benefits in cancer.
• To discuss the clinical utility of HDAC inhibitors, with a focus on their application in leukemia treatment.
• To highlight the potential of HDAC inhibitors as antileukemia agents.

Main Methods:

• Literature review of studies on epigenetic modifications and HDAC inhibitors.
• Analysis of clinical trial data for approved and investigational HDAC inhibitors.
• Examination of preclinical and clinical evidence supporting HDAC inhibition in leukemia.

Main Results:

• HDAC inhibitors demonstrate diverse anticancer mechanisms, including promotion of apoptosis and inhibition of proliferation.
• Combination therapies involving HDAC inhibitors and chemotherapeutic drugs are under active investigation, especially for hematological malignancies.
• Over twenty HDAC inhibitors have been evaluated in clinical trials, with five achieving regulatory approval.

Conclusions:

• HDAC inhibitors represent a significant therapeutic advancement in oncology.
• Their multifaceted anticancer effects position them as valuable agents for leukemia treatment.
• Further research into HDAC inhibitor mechanisms and clinical applications holds promise for improving patient outcomes.